Document Detail


Update on newer antihypertensive medicines and interventions.
MedLine Citation:
PMID:  20472814     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The incidence and prevalence of systemic hypertension are reaching global epidemic proportions. Despite a diverse pharmacologic armamentarium of agents to treat high blood pressure, suboptimal control remains a significant problem in as many as 43% of patients and this rate has not significantly improved over the past 2 decades. There are a variety of factors contributing to this including patient nonadherence due to complex drug regimens and medication side effects, undertreatment, and treatment resistance. There, thus, remains a need to develop novel agents and approaches to antihypertensive therapy that facilitate attainment of optimal blood pressure levels. This monograph will review a number of new pharmacologic targets and interventions as well as a novel method of drug delivery to patients.
Authors:
Katherine C Wu; Gary Gerstenblith
Related Documents :
1381794 - Determining hypertensive end-organ damage in trials: a review of current methodologies ...
933954 - Studies with prazosin--a new effective hypotensive agent. i. open clinical study of pra...
20331334 - Changes in blood pressure during induction of anesthesia and oral and maxillofacial sur...
19821434 - Blood pressure lowering efficacy of reserpine for primary hypertension.
1381794 - Determining hypertensive end-organ damage in trials: a review of current methodologies ...
11766064 - N-methyl-1-deoxynojirimycin (mor-14), an alpha-glucosidase inhibitor, markedly improves...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2010-05-14
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  15     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-10     Completed Date:  2010-12-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  257-67     Citation Subset:  IM    
Affiliation:
Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. kwu@jhmi.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-1 Receptor Antagonists / therapeutic use
Aldosterone Antagonists / therapeutic use
Antihypertensive Agents / adverse effects,  therapeutic use*
Aspartic Acid Endopeptidases / antagonists & inhibitors
Drug Delivery Systems
Drug Resistance
Humans
Hypertension / drug therapy,  immunology,  therapy*
Metalloendopeptidases / antagonists & inhibitors
Patient Compliance
Progestins / therapeutic use
Receptors, Endothelin / antagonists & inhibitors
Vaccines / therapeutic use
Chemical
Reg. No./Substance:
0/Adrenergic beta-1 Receptor Antagonists; 0/Aldosterone Antagonists; 0/Antihypertensive Agents; 0/Progestins; 0/Receptors, Endothelin; 0/Vaccines; EC 3.4.23.-/Aspartic Acid Endopeptidases; EC 3.4.24.-/Metalloendopeptidases; EC 3.4.24.71/endothelin-converting enzyme

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of antihypertensive therapy among ischemic stroke survivors: impact of ischemic heart dis...
Next Document:  Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal--medial ...